시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
아밀로이드증 치료제 시장 규모, 점유율, 성장 분석 : 치료 유형별, 투여 경로별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Amyloidosis Therapeutics Market Size, Share, and Growth Analysis, By Therapy Type, By Route of Administration, By Application, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1819749
리서치사 : SkyQuest
발행일 : 2025년 09월
페이지 정보 : 영문 178 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,652,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,951,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,250,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계 아밀로이드증 치료제 시장 규모는 2023년에 201억 달러로 평가되었으며, 2024년 228억 5,000만 달러에서 2032년에는 638억 3,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 CAGR 13.7%로 증가할 전망입니다.

세계 아밀로이드증 치료제 시장은 아밀로이드증의 유병률과 인지도가 높아지고, 임상 및 진단 기술이 크게 발전하면서 강력한 성장세를 보이고 있습니다. 혁신적인 표적 치료법이 수용되고 있으며, 완화의료 솔루션에 대한 수요가 증가하고 있습니다. 고령화, 특히 유전적 소인을 가진 인구의 증가는 시장 확대에 기여하고 있으며, 유리한 정부 정책과 오펀드럭 우대 정책은 치료제의 채택을 촉진하고 있습니다. 의료 전문가와 환자의 인식이 높아지면 증상을 조기에 발견할 수 있습니다. 또한, AI, 머신러닝, IoT, AR과 같은 기술의 통합은 신약개발, 정밀의료, 환자 모니터링, 영상 진단에 혁명을 일으켜 궁극적으로 아밀로이드증 치료의 치료 성과와 규제 준수를 개선할 수 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

아밀로이드증 치료제 시장 규모 : 치료 종류별 & CAGR(2025-2032년)

아밀로이드증 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)

아밀로이드증 치료제 시장 규모 : 용도별 & CAGR(2025-2032년)

아밀로이드증 치료제 시장 규모 : 최종사용자별 & CAGR(2025-2032년)

아밀로이드증 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)

아밀로이드증 치료제 시장 규모 & CAGR(2025-2032년)

경쟁 정보

주요 기업 개요

결론과 제안

KSM
영문 목차

영문목차

Global Amyloidosis Therapeutics Market size was valued at USD 20.1 billion in 2023 and is poised to grow from USD 22.85 billion in 2024 to USD 63.83 billion by 2032, growing at a CAGR of 13.7% during the forecast period (2025-2032).

The global amyloidosis therapeutics market is experiencing robust growth driven by the increasing prevalence and awareness of amyloidosis, along with significant advancements in clinical practices and diagnostic technologies. The rising acceptance of innovative and targeted therapies enhances the market landscape, generating demand for palliative care solutions. The aging population, particularly those with genetic predispositions, contributes to market expansion, supported by favorable government policies and orphan drug incentives that encourage the adoption of therapeutics. Enhanced awareness among healthcare professionals and patients facilitates the early identification of symptoms. Additionally, the integration of technologies such as AI, machine learning, IoT, and AR is revolutionizing drug discovery, precision medicine, patient monitoring, and diagnostic imaging, ultimately improving treatment outcomes and regulatory compliance in amyloidosis care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Therapeutics Market Segments Analysis

Global Amyloidosis Therapeutics Market is segmented by Therapy Type, Route of Administration, Application, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Stem Cell Transplantation, Targeted Therapy, Supportive Care & Surgery and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Application, the market is segmented into AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis and Wild-Type ATTR. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is significantly driven by the growing incidence of amyloidosis, attributed to heightened awareness and improved diagnostic techniques. This surge in understanding fosters a robust demand for therapeutics specifically targeting the condition. Additionally, the increasing adoption of innovative treatment options and advanced diagnostic methods is propelling market expansion, especially since amyloidosis is a rare disease that frequently remains undetected. Furthermore, enhanced healthcare reimbursement policies play a vital role in promoting both the diagnosis and treatment of amyloidosis, thereby further stimulating the market's growth and accessibility for affected patients.

Restraints in the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market faces several challenges that hinder patient adoption and pharmaceutical investment. The substantial expenses associated with advanced medications, specialized treatments, and ongoing care create financial barriers for individuals seeking amyloidosis therapeutics. Additionally, the high costs involved in researching and developing innovative drugs, including RNA-based therapies, deter pharmaceutical companies from pursuing further exploration in this field. Furthermore, the rare and severe nature of amyloidosis, combined with its potential for fatal outcomes, leads many patients to be reluctant in embracing these therapies. Consequently, these factors collectively contribute to a constrained market environment for amyloidosis treatments.

Market Trends of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is witnessing a significant trend towards the adoption of RNA-based therapies, driven by their heightened efficacy and cost-effectiveness. Patients increasingly favor these therapies as they address the root causes of the disease, providing long-term solutions with fewer doses required. Furthermore, the surge in research and development efforts coupled with innovative advancements from biotech firms and pharmaceutical companies is bolstering patient confidence in RNA-based treatments. This shift reflects a broader movement within the healthcare landscape towards more targeted and sustainable therapeutic options, positioning RNA-based therapies as a pivotal force in the market's evolution.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Amyloidosis Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

Global Amyloidosis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

Global Amyloidosis Therapeutics Market Size by Application & CAGR (2025-2032)

Global Amyloidosis Therapeutics Market Size by End User & CAGR (2025-2032)

Global Amyloidosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

Global Amyloidosis Therapeutics Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기